Alto Neuroscience Appoints New Chief Medical Officer

TL;DR

Alto Neuroscience just hired a new CMO from Genentech to lead their drug development. Big move for their pipeline.

AI Summary

Alto Neuroscience, Inc. announced on May 21, 2024, the appointment of Dr. Jonathan F. Miller as Chief Medical Officer. Dr. Miller, previously a Senior Medical Director at Genentech, brings extensive experience in neuroscience drug development. This appointment is part of Alto's ongoing efforts to advance its pipeline of novel therapies for neurological and psychiatric disorders.

Why It Matters

The appointment of a new Chief Medical Officer with significant industry experience could signal a strategic shift or acceleration in Alto Neuroscience's drug development programs, potentially impacting the company's future clinical trial progress and regulatory submissions.

Risk Assessment

Risk Level: medium — The appointment of a key executive like a CMO is significant, but the filing itself does not contain information about the company's financial health or market performance, necessitating a medium risk assessment.

Key Players & Entities

• Alto Neuroscience, Inc. (company) — Registrant
• Dr. Jonathan F. Miller (person) — Appointed Chief Medical Officer
• Genentech (company) — Dr. Miller's former employer
• May 21, 2024 (date) — Date of Report

FAQ

From the Filing

0001193125-24-143369.txt : 20240521 0001193125-24-143369.hdr.sgml : 20240521 20240521082932 ACCESSION NUMBER: 0001193125-24-143369 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240521 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240521 DATE AS OF CHANGE: 20240521 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alto Neuroscience, Inc. CENTRAL INDEX KEY: 0001999480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 834210124 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41944 FILM NUMBER: 24966913 BUSINESS ADDRESS: STREET 1: 369 SOUTH SAN ANTONIO RD. CITY: LOS ALTOS STATE: CA ZIP: 94022 BUSINESS PHONE: 773-255-5012 MAIL ADDRESS: STREET 1: 369 SOUTH SAN ANTONIO RD. CITY: LOS ALTOS STATE: CA ZIP: 94022 8-K 1 d773656d8k.htm 8-K 8-K false 0001999480 0001999480 2024-05-21 2024-05-21     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024     ALTO NEUROSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter)       Delaware   001-41944   83-4210124 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   369 South San Antonio Road , Los Altos , CA   94022 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (650) 200-0412 N/A (Former name or former address, if changed since last report.)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.0001 par value per share   ANRO   New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On May 21, 2024, Alto Neuroscience, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) appointed Michael Hanley as the Chief Operating Officer of the Company, effective as of May 20, 2024 (the “Appointment Date”). Mr. Hanley, age 51, has served as Founder and Executive Director of Slainte Strategic Consulting LLC since May 2023. Mr. Hanley previously served as the Chief Business Officer and Ch